Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 21, 2007. The report announces a definitive agreement for GSK to acquire Reliant Pharmaceuticals Inc., a privately held specialty pharmaceutical company focused on cardiovascular therapies, for $1.65 billion (GBP 800 million) in cash.
Key Financial Metrics
- Acquisition Price: $1.65 billion (GBP 800 million) in cash.
- Reliant Net Sales (9 months ended Sept 30, 2007): $341 million.
- Reliant Sales Growth (YoY): 62% increase compared to the prior period.
- Lovaza Net Sales (9 months ended Sept 30, 2007): $206 million.
- Lovaza Sales Growth (YoY): 115% increase compared to the first nine months of 2006.
- Lovaza Market Share: 10% of total prescriptions in the non-statin dyslipidemia segment as of September 30, 2007.
- Target Market Size: The non-statin dyslipidemia market totaled approximately $2.2 billion in 2006.
Material Changes and Strategic Rationale
The primary material change is the strategic acquisition of Reliant Pharmaceuticals to expand GSK's cardiovascular portfolio in the United States. The transaction is driven by the addition of Lovaza (omega-3-acid ethyl esters), the only FDA-approved prescription omega-3 medicine for treating very high triglyceride levels. Lovaza has demonstrated rapid uptake since its 2005 launch, achieving a 45% reduction in triglycerides in clinical trials. The acquisition also brings three other in-licensed cardiovascular products: DynaCirc CR, InnoPran XL, and Rythmol SR.
Guidance, Outlook, and Risks
- Earnings Impact: GSK expects the transaction to be slightly accretive to earnings in 2008, excluding integration costs, with additional value creation anticipated in subsequent years.
- Market Outlook: The non-statin dyslipidemia market is expected to grow in excess of 20% annually. GSK views Lovaza as a new driver of sales growth in the US business, complementing existing products like Coreg CR.
- Regulatory Contingency: The acquisition is subject to approval by the US Federal Trade Commission and is expected to conclude before the end of 2007.
- Risk Factors: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks described in GSK's 2006 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the status of US Federal Trade Commission approval for the $1.65 billion acquisition.
- Confirm the timeline for the transaction's expected year-end closure.
- Review the specific integration costs excluded from the 2008 accretive earnings projection.
- Assess the competitive landscape in the non-statin dyslipidemia market, specifically regarding the 20% annual growth projection.
- Validate the supply chain continuity for Lovaza, noting that Pronova BioPharma ASA will continue to supply primary materials.